Last reviewed · How we verify

NCT07349589

Evaluate the Safety, Tolerability and Pharmacokinetics of DW5524 in Healthy Adult Volunteers

Not yet recruiting Phase 1 Last updated 20 January 2026
What this trial tests

Phase 1 trial testing DW5524 in Healthy Adult in 48 participants. Not yet recruiting.

Timeline
1 February 2026
Primary endpoint
28 February 2026
1 December 2026

Quick facts

Lead sponsorDaewon Pharmaceutical Co., Ltd.
PhasePhase 1
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposetreatment
Enrollment48
Start date1 February 2026
Primary completion28 February 2026
Estimated completion1 December 2026
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Daewon Pharmaceutical Co., Ltd. — full company profile →

Who can join

19 and older, any sex, with Healthy Adult. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aimed to evaluate the safety and pharmacokinetic characteristics of DW5524 in healthy adult volunteers.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Healthy Adult

Currently open trials in the same condition.

Other Daewon Pharmaceutical Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07349589.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing